Celcuity

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Celcuity and other ETFs, options, and stocks.

About CELC

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. 

CEO
Brian F. Sullivan
CEOBrian F. Sullivan
Employees
155
Employees155
Headquarters
Minneapolis, Minnesota
HeadquartersMinneapolis, Minnesota
Founded
2012
Founded2012
Employees
155
Employees155

CELC Key Statistics

Market cap
6.73B
Market cap6.73B
Price-Earnings ratio
-35.47
Price-Earnings ratio-35.47
Dividend yield
Dividend yield
Average volume
1.06M
Average volume1.06M
High today
$143.00
High today$143.00
Low today
$136.44
Low today$136.44
Open price
$142.63
Open price$142.63
Volume
652.35K
Volume652.35K
52 Week high
$151.02
52 Week high$151.02
52 Week low
$10.26
52 Week low$10.26

Stock Snapshot

Celcuity(CELC) stock is priced at $138.23, giving the company a market capitalization of 6.73B. It carries a P/E multiple of -35.47.

On 2026-05-24, Celcuity(CELC) stock traded between a low of $136.44 and a high of $143.00. Shares are currently priced at $138.23, which is +1.3% above the low and -3.3% below the high.

The Celcuity(CELC)'s current trading volume is 652.35K, compared to an average daily volume of 1.06M.

During the past year, Celcuity(CELC) stock moved between $10.26 at its lowest and $151.02 at its peak.

During the past year, Celcuity(CELC) stock moved between $10.26 at its lowest and $151.02 at its peak.

CELC News

Simply Wall St 7h
Assessing Celcuity Valuation As Shares Cool After A Strong Year-Long Run

Celcuity (CELC) has drawn investor attention after recent trading that left the stock around $138.23, supported by a clinical stage pipeline focused on targeted...

Assessing Celcuity Valuation As Shares Cool After A Strong Year-Long Run
TipRanks 2d
Citizens biotech analysts hold a dinnermeeting at ASCO

Biotech Analysts hold a Key Opinion Leader Dinner Meeting at ASCO to discuss novel therapeutics for breast cancer (relevant companies CELC, RLAY, ARVN, ZYME, GI...

TipRanks 5d
Celcuity’s Gedatolisib Shines Amid Mounting Cash Burn

Celcuity Inc. ((CELC)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level data and power...

Analyst ratings

100%

of 12 ratings
Buy
100%
Hold
0%
Sell
0%

More CELC News

TipRanks 6d
Celcuity Shareholders Approve New 2026 Equity Incentive Plans

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 7d
Celcuity price target raised to $185 from $165 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Celcuity (CELC) to $185 from $165 and keeps a Buy rating on the shares. With th...

People also own

Based on the portfolios of people who own CELC. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.